Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ipsen and Exelixis report positive data from hepatocellular carcinoma drug trial

Ipsen and Exelixis report positive data from hepatocellular carcinoma drug trial

18th January 2018

Ipsen and Exelixis have announced the findings of a new clinical trial showing the effectiveness of a new treatment for hepatocellular carcinoma.

Data from the phase III CELESTIAL trial showed that the drug cabozantinib offered benefits compared to placebo when given to previously-treated advanced hepatocellular carcinoma patients.

Cabozantinib was associated with a statistically significant and clinically meaningful improvement in overall survival, while progression-free survival was more than doubled and objective response rates and disease control levels were also much higher.

Based on these positive results, Ipsen and Exelixis expect to file a variation of the initial application to the European Medicines Agency and other relevant regulatory agencies in the first half of 2018.

Dr Alexandre Lebeaut, executive vice-president for research and development and chief scientific officer at Ipsen, said: "Patients diagnosed with advanced hepatocellular carcinoma urgently need new treatment options. The positive results of the pivotal phase III CELESTIAL trial are encouraging for both physicians and patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.